ANDREA SLOAN, an ovarian cancer patient whose efforts to get access to a BioMarin drug attracted national media attention, died from complications of pneumonia Jan. 1 (The Cancer Letter, Nov. 8, 2013). Sloan, an Austin attorney, was 45.
Andrea Sloan, Prominent Ovarian Cancer Patient Dies
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Table of Contents
YOU MAY BE INTERESTED IN
How’s this for a paradox: The better cancer centers become at keeping patients alive, the more expensive cancer care becomes. This brutal tradeoff hits harder in rural areas, where the cancer burden is higher and the investigator and clinical trial representation is lower.


HHS earlier this week rolled out a cluster of initiatives related to simplifying clinical trials, presenting these measures as a government-wide effort to maintain America’s leadership in early-stage drug development.


The world of cancer research has lost one of its brightest and gentlest stars, Joseph F. Fraumeni, Jr., MD, the founding director of NCI’s Division of Cancer Epidemiology and Genetics within the Intramural Research Program of the National Institutes of Health.


Some lives leave their mark not only on the people who loved them, but also on the very places where others come to seek hope. Karen Haight Huntsman’s was such a life.


When Robert Mayer was only a few years out of residency, in the 1970s, he signed on as an investigator of the NCI-supported Gastrointestinal Tumor Study Group, which conducted research into colorectal, gastric, and pancreatic cancers.





